Lincoln Pharma develops oral spray version of Ondansetron
Lincoln Pharmaceuticals Ltd said it developed and
launched an oral spray version of
Ondansetron anti-nausea drug.
Ondansetron is used to prevent nausea and
vomiting caused by cancer drug treatment (chemotherapy), radiation therapy and
also in the prevention and treatment for nausea and vomiting after surgery. The
medication is also more helpful during motion sickness.
Presently the Ondansetron formulation is
available in the form of Tablet, Syrup and Injectable.
Ondansetron as Oral spray is developed first
time in India as it the formulation is only available in U.S. market only, the
company said. The medication was developed at the company´s manufacturing unit
near Ahmedabad.
The Pharma company has done the
Bio-Equivalent Study for Ondansetron Oral Spray and got the DCGI permission. The
all India level anti-emetic drug market, which includes Ondansetron, is Rs. 678
Crores. It has an all over India market of Rs. 303 Crores.
Lincoln offers products, such as tablets,
capsules, liquid injection, cream in tubes, dry power injection, liquid in
bott, liquid injection and pharma products.
Its products include Tinnex, which is a
medication for treating cochlear synaptic tinnitus; Pa 12 Proglet, which is a
1000 milligram programmed released paracetamol that is developed to offer
control of pain and fever; and ARH 1, which is an anti-malarial drug that is
formulated utilizing technology known as dose optimization technology.
Comments
Post a Comment